BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers

Accessibility StatementSkip Navigation - GLIX1 restores TET2 activity in cancer, resulting in double stranded DNA breaks in cancer cells only - - FDAÂ IND clearance received for Phase 1/2a study, expected to initiate in Q1 2026 - -Â Glioblastoma market opportunity estimated to be in excess of $3.8 billion annually across the US and EU5 by 2030 - -Â BioLineRx affirms its cash runway into the first half of 2027 - Urgent Unmet Need and Significant Commercial Opportunity in Glioblastoma GBM is the most common a ...